MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Locally Advanced Gastric Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Locally Advanced Skin Squamous Cell Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Clinical Stage IVB Gastric Cancer AJCC v8
Locally Advanced Renal Cell Carcinoma

Interventions: Drug: Cyclophosphamide
Biological: Neoantigen Peptide Vaccine
Biological: Pembrolizumab
Biological: Sargramostim

First Posted Date: 2022-03-08

Last Posted Date: 2024-06-12

Lead Sponsor: Mayo Clinic

Target Recruit Count: 36

Registration Number: NCT05269381

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Ketamine and Kidney Injury in Cardiac Surgery

Phase 4

Recruiting

Conditions: Cardiac Surgery

Interventions: Drug: Ketamine
Drug: Propofol

First Posted Date: 2022-03-07

Last Posted Date: 2025-01-08

Lead Sponsor: Mayo Clinic

Target Recruit Count: 200

Registration Number: NCT05268562

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion

Phase 4

Recruiting

Conditions: Type 2 Diabetes
Obesity
Healthy

Interventions: Drug: Dextrose
Drug: Clinisol 15%

First Posted Date: 2022-03-03

Last Posted Date: 2024-05-29

Lead Sponsor: Mayo Clinic

Target Recruit Count: 60

Registration Number: NCT05264727

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

Cluster Headache Treatment With Rimegepant

Phase 2

Recruiting

Conditions: Cluster Headache

Interventions: Drug: Rimegepant

First Posted Date: 2022-03-03

Last Posted Date: 2024-03-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 10

Registration Number: NCT05264714

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

Clinical Impact of Cardiac Photon Counting CT

Not Applicable

Active, not recruiting

Conditions: Coronary Artery Disease

Interventions: Diagnostic Test: Photon counting computed tomography (PC-CT)

First Posted Date: 2022-02-15

Last Posted Date: 2024-07-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 450

Registration Number: NCT05240807

Locations: 🇺🇸
Boleyn Andrist, Eyota, Minnesota, United States

Remote EEG Device for Identification of Risk for Neonatal Seizures

Not Applicable

Withdrawn

Conditions: Neonatal Encephalopathy

Interventions: Device: Epilog device

First Posted Date: 2022-02-15

Last Posted Date: 2024-08-19

Lead Sponsor: Mayo Clinic

Registration Number: NCT05239585

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Research for Individualized Therapeutics in Rare Genetic Disease

Conditions: Undiagnosed Diseases
Rare Genetic Disease

Interventions: Other: Individualized drug matching per genetic disease

First Posted Date: 2022-02-11

Last Posted Date: 2024-02-20

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT05236595

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic Rochester, Minnesota, Minnesota, United States

Infiltration of Gadolinium Injection in Brain MR Scans Using Artificial Intelligence

Completed

Conditions: Magnetic Resonance Imaging

First Posted Date: 2022-02-11

Last Posted Date: 2022-04-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 40

Registration Number: NCT05235646

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

Completed

Conditions: Fungal Infection
Candidiasis

First Posted Date: 2022-02-11

Last Posted Date: 2024-10-09

Lead Sponsor: Mayo Clinic

Target Recruit Count: 87

Registration Number: NCT05235711

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Phase 1

Recruiting

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Human Papillomavirus-Related Carcinoma
Locally Advanced Oropharyngeal Carcinoma
Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Interventions: Biological: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
Procedure: Computed Tomography
Biological: Pembrolizumab
Procedure: FDG-Positron Emission Tomography
Procedure: Biospecimen Collection
Procedure: Biopsy

First Posted Date: 2022-02-10

Last Posted Date: 2024-05-24

Lead Sponsor: Mayo Clinic

Target Recruit Count: 24

Registration Number: NCT05232851

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy